Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis
Findings from this study indicate that the remyelinating and immunomodulatory effects of the KOR agonist NalF can be significantly enhanced through interactions with the MOR antagonist NalM in a distinct dose-dependent manner.
Authors
- Nikki Templeton
- Anne Camille La Flamme (ORCID: https://orcid.org/0000-0002-2344-7281)
- Thomas Edward Prisinzano (ORCID: https://orcid.org/0000-0002-0649-8052)
- Lisa Denny
- Bronwyn M. Kivell (ORCID: https://orcid.org/0000-0001-9699-553X)
- Katharina Robichon (ORCID: https://orcid.org/0000-0001-6638-2679)
- Mackenzie Kiernan
Institutions
- University of Kentucky (US)
- Malaghan Institute of Medical Research (NZ)
- Victoria University of Wellington (NZ)
- University of Otago (NZ)
Publication Details
- Journal
- Clinical & Translational Immunology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cti2.70069
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Victoria University of Wellington
- Victoria University
- Ministry of Business, Innovation and Employment